Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

키워드

참고문헌 (43)

1. Suh DJ, "Current status of hepatitis C virus infection in Korea", Intervirology, 49, pp.70~75 (2006)
2. Gower E, "Global epidemiology and genotype distribution of the hepatitis C virus infection", J Hepatol, 61(1 Suppl), pp.S45~S57 (2014)
3. Smolders EJ, "Pharmacokinetics, efficacy, and safety of hepatitis c virus drugs in patients with liver and", or renal impairment, 2016, pp.39, 589~611
4. Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
5. 진동찬, "Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients", Kidney Research and Clinical Practice, 35(4), pp.204~211 (2016), 대한신장학회
6. Isnard Bagnis C, "Hepatitis C therapy in renal patients:who, how, when?", Infect Dis Ther, 5, pp.313~327 (2016)
7. Carvalho-Filho RJ, "Management of hepatitis C in patients with chronic kidney disease", World J Gastroenterol, 21, pp.408~422 (2015)
8. Racanelli V, "Hepatitis C virus infection : when silence is deception", Trends Immunol, 24, pp.456~464 (2003)
9. Thomson EC, "The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals", J Gen Virol, 92, pp.2227~2236 (2011)
10. Omata M, "APASL consensus statements and recommendation on treatment of hepatitis C", Hepatol Int, 10, pp.702~726 (2016)
11. Patel PR, "Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients", Am J Kidney Dis, 56, pp.371~378 (2010)
12. Hardy NM, "Antibody to hepatitis C virus increases with time on hemodialysis", Clin Nephrol, 38, pp.44~48 (1992)
13. Niu MT, "Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members", Am J Kidney Dis, 22, pp.568~573 (1993)
14. Thompson ND, "Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008", Ann Intern Med, 150, pp.33~39 (2009)
15. Thompson ND, "Hepatitis C virus transmission in hemodialysis units : importance of infection control practices and aseptic technique", Infect Control Hosp Epidemiol, 30, pp.900~903 (2009)
16. Girou E, "Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit", Clin Infect Dis, 47, pp.627~633 (2008)
17. Bialek SR, "The changing epidemiology and natural his tory of hepatitis C virus infection", Clin Liver Dis, 10, pp.697~715 (2006)
18. Prati D, "Transmission of hepatitis C virus by blood transfusions and other medical procedures : a global review", J Hepatol, 45, pp.607~616 (2006)
19. "Recommendations for preventing transmission of infections among chronic hemodialysis patients", MMWR Recomm Rep, 50, pp.1~43 (2001)
20. Webster DP, "Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin", Int J STD AIDS, 24, pp.179~183 (2013)
21. Webster DP, "Hepatitis C", Lancet, 385, pp.1124~1135 (2015)
22. Lemos LB, "Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis", J Clin Gastroenterol, 42, pp.208~211 (2008)
23. Okuda K, "Acute hepatitis C among renal failure patients on chronic haemodialysis", J Gastroenterol Hepatol, 13, pp.62~67 (1998)
24. Brown DL, "A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies", Obstet Gynecol, 91, pp.641~642 (1998)
25. Fabrizi F, "The impact of hepatitis C virus infection on survival in dialysis patients : metaanalysis of observational studies", J Viral Hepat, 14, pp.697~703 (2007)
26. Scott DR, "Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand", Transplantation, 90, pp.1165~1171 (2010)
27. Kidney Disease: Improving Global Outcomes, "KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease", Kidney Int Suppl, (109), pp.S1~S99 (2008)
28. Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
29. Engel M, "Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil", BMC Public Health, 7, pp.50~ (2007)
30. Liu CH, "Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C", Clin Infect Dis, 51, pp.541~549 (2010)
31. Bhamidimarri KR, "Finally, safe and effective treatment options for hepatitis C in hemodialysis patients", J Hepatol, 65, pp.7~10 (2016)
32. Gane EJ, "Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C", N Engl J Med, 368, pp.34~44 (2013)
33. Hundemer GL, "Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency", Infect Dis(Lond), 47, pp.924~929 (2015)
34. Korean Association for the Study of the Liver, "KASL clinical prractice guidelines management of hepatitis C : Treatment of chronic hepatitis C", pp.1~152 (2017), Jin Publishing Co.
35. European Association for the Study of the Liver, "EASL Recommendations on Treatment of Hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)
36. "Hepatitis C guidance: Recommendations for testing, managing, and treating hepatitis C virus"[URL]
37. Saxena V, "Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function", Liver Int, 36, pp.807~816 (2016)
38. Bhamidimarri KR, "Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease", J Hepatol, 63, pp.763~765 (2015)
39. Desnoyer A, "Pharmacokinetics, safety and efficacy of a full dose sofosbuvirbased regimen given daily in hemodialysis patients with chronic hepatitis C", J Hepatol, 65, pp.40~47 (2016)
40. Pockros PJ, "Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease", Gastroenterology, 150, pp.1590~1598 (2016)
41. Suda G, "Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C", J Gastroenterol, 51, pp.733~740 (2016)
42. Roth D, "Grazoprevir plus elbasvir in treatment-naive and treatmentexperienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease(the C-SURFER study) : a combination phase 3 study", Lancet, 386, pp.1537~1545 (2015)
43. Gane E, "Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment", N Engl J Med, 377, pp.1448~1455 (2017)

관련 논문AI추천